ArticleThe Journal of small animal practice2026
Clinical, pathological and prognostic features of surgically excised cutaneous and subcutaneous digital and distal limb mast cell tumours in dogs.
Article in The Journal of small animal practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Triple-Phase Computed Tomography for Differentiating Canine Cutaneous and Subcutaneous Mast Cell Tumors From Benign Lesions: A Size-Based Evaluation.Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate clinical, pathological and prognostic features and outcomes of dogs with surgically excised cutaneous and subcutaneous digital or distal limb mast cell tumours. MATERIALS AND
methodsMedical records between 2014 and 2024 were reviewed, and signalment, clinicopathological testing, tumour location, recurrence, complications and histological characteristics were recorded. Additionally, progression-free interval and overall survival time were evaluated. One hundred and fifteen client-owned dogs with mast cell tumour admitted to two academic institutions were included.
resultsSurgical complications occurred in 38% of dogs with surgical site infection and incisional dehiscence most common. Local recurrence occurred in 23% of dogs overall, with completely excised tumours having 10% recurrence, narrowly excised 20% and incompletely excised 35%. Higher recurrence rates occurred with incomplete surgical margins, mitotic count >5 and histologically high-grade mast cell tumours. The median progression-free interval was significantly longer for wide excision (2270 days) compared to marginal excision (888 days). The overall survival time was 7 years for all dogs overall, was not reached for low-grade mast cell tumours and was 3 years for high-grade mast cell tumours. The progression-free interval and overall survival time were affected by tumour grade but not lymph node status. CLINICAL SIGNIFICANCE: The behaviour of canine mast cell tumours affecting the digits and distal limb was affected primarily by tumours grade. Recurrence rates were highest in dogs with high-grade mast cell tumours, incomplete surgical resection and a mitotic count of >5. The outcome with surgical excision is excellent. Future studies are needed to further evaluate the effects of adjuvant chemotherapy, metastatic lymph node status and lymph node extirpation in high-grade mast cell tumour cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.